Moderna, Inc.’s packaging strategy for its COVID-19 vaccine booster is raising concerns among immunization registry system operators, pharmacists and health care practitioners who say it will complicate vaccine and inventory management and tracking and could make postauthorization safety and effectiveness surveillance more challenging.
The US Food and Drug Administration has authorized a single booster dose of the mRNA vaccine for three high-risk groups...






